Back to Search
JOEL ENGELMAN, PHD
PHD
Clinical Psychologist
NPI: 1235964826Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
PMID 19106609·Cell Cycle·2009
6-review
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
PMID 19629070·Nat Rev Cancer·2009
6-review
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
PMID 19447865·Clin Cancer Res·2009
7-preclinical
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
PMID 19237633·J Clin Oncol·2009
8-other
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
PMID 18458038·J Clin Oncol·2008
3-trial
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
PMID 18483355·Clin Cancer Res·2008
6-review
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2400 N Havenwood Dr
Columbus, OH 43209 - Phone
- (347) 415-3799
Quick Facts
- NPI
- 1235964826
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile